Individual Sensitivity for Interstitial Lung Diseases
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Interstitial lung diseases (ILD) is a collective noun for various chronic lung diseases, including sarcoidosis and idiopathic lung fibrosis (IPF). Sarcoidosis is a multi-systemic disease that includes damage to the lungs in 90% of the patients. Generally, the disease can be described as a systemic, granulomatous and antigen-driven disorder. IPF is a disease of only the lungs, in which an unknown cause induces a strong inflammation reaction leading to acute lung damage that ultimately results in the formation of scar tissue and stiffness of the lungs.
Unfortunately, the exact cause of ILD is still unknown. It is suggested that environmental and work-related exposure to various triggers can exert an effect on the course of the diseases. Examples of such triggers include bacteria, organic agents such as pollen and cotton dust and inorganic agents like metals and talc. Due to this unknown cause, it is difficult to treat ILD. Consequently, the current guideline is no medication or anti-inflammatory agents in severe cases. Unfortunately, this therapy is not completely effective.
Triggers that are suggested to cause ILD can exert their effects via various mechanisms. On the one hand, they can induce an inflammatory reaction as we recently demonstrated for various triggers including instillation material and sicila. During such an inflammatory reaction, cytokines are released that can induce oxidative stress, i.e. an imbalance between the formation of and the protection against reactive oxygen species (ROS). On the other hand, ILD-inducing triggers may directly cause an increased ROS production that subsequently can evoke an inflammatory reaction.
The objective of the current study is to investigate the individual sensitivity for the development of ILD after exposure to various triggers. Main focus will be the differences in the formation of and the protection against ROS as well as the occurring inflammatory reaction after exposure to such triggers.
Furthermore, a simple blood test will be developed to study and eventually even predict the individual reaction of subjects to various triggers.
Finally, to fully characterize the development of ILD after exposure to various triggers, the exhaled air of patients will be studied in order to identify specific markers of oxidative stress and damage.
| Condition |
|---|
|
Interstitial Lung Diseases |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Individual Sensitivity for Interstitial Lung Diseases |
- differences in the production of and the protection against ROS [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- differences in the occurring inflammatory reaction [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
- differences in the presence of so-called volatile organic compounds (VOCs) in the exhaled air [ Time Frame: 0 hour ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
The patients will be asked to donate 5L exhaled air and 20 ml blood.
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2008 |
| Study Completion Date: | September 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| 1 |
| 2 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Participants in this study include both men and women, who are 18 years of age or older and diagnosed with ILD using lung biopsy, X ray or BALF (broncho-alveolar lavage fluid) analysis and are either treated for this with anti-inflammatory agents or not. There's no maximum age set for this study since ILD can occur at all ages. Additional criteria are non smoking, no pregnancy or lactation and no use of vitamins or nutritional supplements.
The inclusion of both treated and untreated patients enables us to study the effectiveness of anti-inflammatory agents on a larger scale.
Inclusion Criteria:
- ILD diagnosis confirmed by lung biopsy, X ray or BALF analysis
Exclusion Criteria:
- smoking
- pregnancy or lactation
- use of vitamins or nutritional supplements
Contacts and Locations| Netherlands | |
| Maastricht University | |
| Maastricht, Netherlands | |
| Study Chair: | Aalt Bast, PhD | Maastricht University |
| Study Director: | Marjolein Drent, PhD, MD | Maastricht University Medical Center |
| Principal Investigator: | Agnes W Boots, PhD | Maastricht University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr. A.W. Boots, Maastricht University |
| ClinicalTrials.gov Identifier: | NCT00741572 History of Changes |
| Other Study ID Numbers: | MEC 08.3.048 |
| Study First Received: | August 25, 2008 |
| Last Updated: | September 23, 2009 |
| Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Maastricht University Medical Center:
|
sarcoidosis fibrosis oxidative stress |
inflammation triggers individual sensitivity |
Additional relevant MeSH terms:
|
Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 19, 2013